Jet Capital Investors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-562,649
| Closed | -$1.27M | – | 36 |
|
|
2023
Q3 | $1.27M | Buy |
+562,649
| New | +$1.27M | 1.9% | 15 |
|
|
2023
Q2 | – | Sell |
-2,761,301
| Closed | -$5.52M | – | 34 |
|
|
2023
Q1 | $5.52M | Hold |
2,761,301
| – | – | 1.87% | 13 |
|
|
2022
Q4 | $5.52M | Hold |
2,761,301
| – | – | 2.1% | 11 |
|
|
2022
Q3 | $5.52M | Buy |
2,761,301
+100,000
| +4% | +$200K | 1.15% | 11 |
|
|
2022
Q2 | $4.66M | Hold |
2,661,301
| – | – | 1.51% | 20 |
|
|
2022
Q1 | $3.59M | Hold |
2,661,301
| – | – | 0.56% | 30 |
|
|
2021
Q4 | $3.59M | Buy |
+2,661,301
| New | +$3.59M | 0.95% | 20 |
|
|
2021
Q3 | – | Sell |
-2,661,301
| Closed | -$3.46M | – | 48 |
|
|
2021
Q2 | $3.46M | Hold |
2,661,301
| – | – | 0.66% | 21 |
|
|
2021
Q1 | $2.53M | Buy |
2,661,301
+2,261,301
| +565% | +$2.15M | 0.44% | 31 |
|
|
2020
Q4 | $276K | Buy |
+400,000
| New | +$852K | 0.07% | 25 |
|
|
2020
Q1 | – | Sell |
-800,000
| Closed | -$2.41M | – | 37 |
|
|
2019
Q4 | $2.41M | Buy |
+800,000
| New | +$2.08M | 0.46% | 30 |
|
Jet Capital Investors's BMY.RT Position: Q4 2023 in Review
Jet Capital Investors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2023, closing a stake of 562,649 shares — an estimated $1.27M sold.
Jet Capital Investors first reported a position in BMY.RT in Q4 2019 and held it in 11 quarters. The position peaked at $5.52M in Q3 2022. 1 fund tracked by Wall St. Rank holds BMY.RT as of Q4 2023.
- Jet Capital Investors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2023 after selling out during the quarter.
- Jet Capital Investors sold 562,649 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2023, an estimated $1.27M.
- Jet Capital Investors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 11 quarters.
- Jet Capital Investors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $5.52M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2023.
Based on Jet Capital Investors's 13F filing for Q4 2023, filed 14 Feb 2024.